"Our impressive results for the quarter are a testament to the strength of our late stage markets, the value of our business model and the expertise and determination of our associates worldwide," said Chairman and CEO Candace Kendle, PharmD. "Coupled with our broad therapeutic and geographic reach, we believe we are well positioned to achieve our strategic growth initiatives and to meet our customers emerging outsourcing needs."
Income from operations for the three months ended Sept. 30, 2008, was $15.9 million, or 12.7 percent of net service revenues, compared to income from operations of $14.2 million, or 14.2 percent of net service revenues, for the same period of the prior year.
Cash flow from operations for the third quarter 2008 was $6.7 million compared with $13.7 million for the same period in 2007. Cash and marketable securities at Sept. 30, 2008, totaled $18.4 million, including $850,000 of restricted cash, compared with $29.1 million, which included $1.2 million of restricted cash at Sept. 30, 2007. In addition to the convertible notes that were outstanding at Sept. 30, 2008, the Company had $2.0 million of debt outstanding under its revolving credit facility. Days sales outstanding in accounts receivable were 46 days for the third quarter 2008 compared with 40 days for the same period of the prior year. Capital expenditures totaled $6.1 million compared with $3.4 million for the same period in 2007.
Net income for the nine months ended Sept. 30, 2008, was $24.4 million
or $1.63 on a diluted basis, an increase of 98 percent, comp
|SOURCE Kendle International Inc.|
Copyright©2008 PR Newswire.
All rights reserved